Skip to main content
B

BUKWANG PHARMACEUTICAL IND CO.,LTD — Investor Relations & Filings

Ticker · 003000 ISIN · KR7003000007 KO Manufacturing
Open in API
Filings indexed 322 across all filing types
Latest filing 2026-01-05 M&A Activity
Country KR South Korea
Listing KO 003000

About BUKWANG PHARMACEUTICAL IND CO.,LTD

https://www.bukwang.co.kr/en/

Bukwang Pharmaceutical is a research and development-focused company that develops, produces, and sells a range of pharmaceutical and oral hygienic products. The company emphasizes an open innovation strategy, leveraging joint ventures, research collaborations, and strategic investments to build a robust drug pipeline. Its key development areas include treatments for central nervous system disorders like schizophrenia, bipolar depression, and dyskinesia in Parkinson's disease. The pipeline also features oncology candidates, such as a treatment for metastatic prostate cancer. Bukwang Pharmaceutical manufactures various dosage forms, including oral solids and injections, alongside over-the-counter medications.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항
M&A Activity Classification · 1% confidence The document is a regulatory filing from Bukwang Pharmaceutical announcing its selection as the final acquirer of Korea Union Pharm, which is currently under rehabilitation proceedings. The content details the acquisition method (third-party capital increase), the acquisition amount (30 billion KRW), and the status of the M&A process. This falls squarely under M&A activity (TAR).
2026-01-05 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (Bukwang Pharm) submitted to the Korea Exchange (KRX). It details a 'Major Management Matter' regarding the application for a Phase 3 clinical trial (IND) for a drug. Since this is a specific regulatory disclosure of a material event that does not fit into categories like financial reports, dividends, or M&A, it falls under the general regulatory filing category.
2025-12-22 Korean
투자판단관련주요경영사항
M&A Activity Classification · 1% confidence The document is an official announcement regarding a conditional investment agreement for the acquisition of Korea Union Pharm by Bukwang Pharm. It details the M&A process, the stalking-horse bid structure, and the involvement of the Seoul Rehabilitation Court. Since this document specifically concerns a merger and acquisition activity, it falls under the M&A Activity category.
2025-12-17 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 1% confidence The document is a short regulatory announcement from Bukwang Pharmaceutical regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the 66th Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of a corporate action (setting a record date). Given its nature as a regulatory notification of a specific corporate event, it fits best under the general regulatory filing category.
2025-12-16 Korean
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement from Bukwang Pharmaceutical regarding the setting of a record date for shareholder registry closure for the purpose of cash and in-kind dividends. This is a standard corporate action announcement related to dividend distribution procedures, which falls under the category of dividend-related notices.
2025-12-16 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Regulatory Filings
2025-10-21 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.